CAR-T therapy for multiple myeloma with kidney problems
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new type of cell therapy (CAR-T cells) for people with multiple myeloma who also have kidney problems. It aims to see if this treatment can help keep the cancer in remission after initial therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 14 years of age or older.
- You have been diagnosed with multiple myeloma along with kidney problems, and you have received at least two rounds of standard treatment.
- Your disease is in a good state of remission (at least partial response) after treatment.
- You have good veins for blood draws and infusions.
- You are not pregnant or breastfeeding, and you do not have a serious infection, active hepatitis, HIV, or a history of organ transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of treatment using your own immune cells (called CAR-T cells) that target two proteins on myeloma cells: BCMA and GPRC5D. It's for people whose myeloma has come back or stopped responding to standard treatments, and who may have few other options left.
This Phase 1/2 study tests a personalized CAR-T cell treatment that targets a protein called BCMA on myeloma cells. It’s designed for people with multiple myeloma who have already tried several other treatments and still have measurable disease.
This trial tests a new treatment called CAR-T cell therapy for people with multiple myeloma that has come back or not responded to other treatments. The treatment uses your own immune cells, modified in a lab to attack the cancer, and may be an option after a stem cell transplant has not worked.
This trial tests a new treatment that combines a stem cell transplant with special immune cells (called CAR-T cells) to fight multiple myeloma. The goal is to see if this combined approach helps people with newly diagnosed myeloma achieve better control of their disease.
This trial tests a special type of immune therapy called CAR T cells, which are made from your own blood cells and then given back to you to fight the cancer. It is for people with multiple myeloma who have not gotten better with other treatments or whose cancer has come back.
This trial tests a new type of immunotherapy called CAR-T cells that target two proteins (BCMA and FcRL5) on myeloma cells. It is for people whose myeloma has returned or not responded to other treatments.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.